We obtained good results with bevacizumab in the treatment of recalcitrant rhinorrhea due to hereditary hemorrhagic capillary dilation (HHT), which can reduce or stop bleeding and improve patients’ quality of life. Intractable rhinorrhea is the most common clinical manifestation of HHT, and repeated heavy rhinorrhea often leads to severe anemia and transfusion-dependent bleeding. Current methods of hemostasis can only reduce bleeding and cannot cure it. Bevacizumab, known by its trade name Avastin, is a recombinant humanized anti-VEGF monoclonal antibody manufactured by Roche Pharmaceuticals International Group, Inc. and was the first angiogenesis inhibitor approved for marketing by the U.S. Food and Drug Administration (FDA). The drug is available at a concentration of 25 mg/ml in 100 mg (4 ml) and 400 mg (16 ml) and needs to be stored in a refrigerator at 2-8°C away from light. Treatment of intractable rhinorrhea due to HHT includes intravenous injection and topical application in the nasal cavity. Intravenous injection of 5mg/kg is given every 2 weeks for at least 2 times, and then once a year to maintain the efficacy. Adverse effects are rare, and individual patients may have headache. Intranasal application can be given as a submucosal injection or as a nasal spray. 25-100 mg (1-4 ml) of bevacizumab is injected into the lateral wall of the nasal cavity, the nasal floor and the nasal septum, and other areas, and may be injected several times. 50-100mg (2-4ml) of bevacizumab in a standard quantified spray bottle with bilateral nasal sprays for long-term application to maintain efficacy.